BL-5923

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameBL-5923
Drug Alias NameCcr1 antagonist (Novartis AG/National Institute of Allergy and Infectious Diseases/MD Anderson Cancer Center)BL-5923
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 1 antagonists
TargetsC-C chemokine receptor type 1
Therapy Area/IndicationsLupus NephritisDiabetic NephropathiesLiver Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis AgThe University Of Texas MD Anderson Cancer CenterNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsN/A
Inactive IndicationsLupus NephritisDiabetic NephropathiesLiver Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A